Evidence map›Paper›PMID 32669913›Full record

ReviewDegenerative neurological and neuromuscular disease2015

Critical appraisal of rotigotine transdermal system in management of Parkinson's disease and restless legs syndrome - patient considerations.

Tigran Kesayan, Jessica D Shaw, Tracy M Jones, Joseph S Staffetti, Theresa A Zesiewicz

Erratum issuedOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Degenerative neurological and neuromuscular disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tigran KesayanDepartment of Neurology, Morsani College of Medicine, University of South Florida.
Jessica D ShawDepartment of Neurology, Morsani College of Medicine, University of South Florida.
Tracy M JonesDepartment of Neurology, Morsani College of Medicine, University of South Florida.
Joseph S StaffettiDepartment of Neurology, Morsani College of Medicine, University of South Florida.
Theresa A ZesiewiczDepartment of Neurology, Morsani College of Medicine, University of South Florida.
University of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rotigotine (RTG) is a dopamine agonist that is used as mono and adjunct therapy to treat Parkinson's disease, and as therapy for moderate-to-severe restless legs syndrome. RTG is the only dopamine agonist currently available as a 24-hour/day transdermal system, providing once-a-day dosing. As a transdermal patch, RTG bypasses the gastrointestinal tract, making it a treatment option for patients with dysphagia. The use of RTG also avoids the need to schedule administration of medication around meals. This review provides a critical appraisal of RTG as treatment of Parkinson's disease and RLS.

Indexed as

dopamine agonistParkinson’s diseaserestless legs syndromerotigotine

Identifiers

PMID32669913
PMCPMC7337197
OpenAlexW1846266592

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.